Creo Medical Share Discussion Threads

[mikeh30] 31/1/2024 16:17

Anyone alive in here?

[wan] 25/1/2024 16:00

As a reminder and for those who are relatively new -

Released: 23/05/2022
Collaboration agreement with Intuitive

Creo technology to be adapted for use with robotic-assisted surgical platform

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it has signed a long-term, multi-year collaboration agreement (the "Agreement") with Intuitive to optimise certain Creo products to be compatible with Intuitive's robotic technology. Intuitive (Nasdaq: ISRG) is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery.

Full Creo release -

[wan] 25/1/2024 15:52

As previously highlighted, Intuitive Surgical disclosed plans for a fifth-generation da Vinci robot on the company’s quarterly earnings call Tuesday.

Published Jan. 24, 2024
Robot reveal: Intuitive submits 510(k) for next-generation system
The new surgical robot will have 10,000 times the processing power of the current da Vinci model

The robotic surgery leader submitted a 510(k) application for da Vinci 5 to the Food and Drug Administration in August, after completing a multicenter investigational device exemption study, Guthart said. The company is now responding to the FDA’s questions, which he called in line with “normal expectations for a submission of this type.”

When the robot will launch depends on the time required to answer those questions, Guthart said.

“It is our hope that it is a ’24 launch,” he added. “But I can’t guarantee it.”

The company plans a phased market introduction over the first several quarters after gaining FDA clearance. Intuitive is also in talks with regulators in Japan and Korea on commercializing da Vinci 5, according to Guthart.

As to what new features the robot will offer, Guthart said more details will be shared once the device is cleared. But the system has been designed to provide 10,000 times the processing power of its predecessor, for gathering data, improving sensing, and delivering better digital and analytic performance.

Intuitive is seeking broad indications for the new robot, aiming initially for greater penetration in current surgical categories, followed by expansion into additional areas, Guthart said.
Full story -

[mikeh30] 25/1/2024 14:44

Bounce point incoming

[wan] 24/1/2024 08:44

J&J expects strong procedure volumes in 2024
After reporting growth for its procedure-based units in the fourth quarter, J&J forecast surgery volumes to be above pre-pandemic levels this year.

Published Jan. 23, 2024

The company reiterated its guidance of 5%-6% operational sales growth and the goal for new products to generate one-third of revenue by 2027, both of which were given during its December investor day. J&J ended the year with several developments in competitive and growing medtech markets, including an updated timeline for Ottava, its soft tissue surgical robot to take on Intuitive Surgical’s da Vinci system

Full story -

[wan] 24/1/2024 08:39

Intuitive exceeded the consensus of Wall Street analysts.

Intuitive seeks FDA clearance for its next-gen da Vinci 5
JANUARY 23, 2024 BY CHRIS NEWMARKER

News of Intuitive moving forward with a next-generation da Vinci system has been much anticipated. Intuitive officials had previously stayed quiet on the timing, especially after the company’s stock took a temporary hit a year ago when Guthart mentioned there would not be a new multiport system launch in 2023.

This evening, Guthart announced that Intuitive has completed a comprehensive multicenter IDE trial for the da Vinci 5. The trial finished accruing patients in May 2023, with Intuitive submitting for 510(k) clearance in August 2023. The company is responding to the FDA’s questions, which Guthart described as falling within normal expectations.

In addition, Intuitive has initiated conversations about da Vinci 5 with regulators in Japan and South Korea, according to Guthart.

Intuitive Surgical CFO Jamie Samath outlined how Intuitive is gearing up for da Vinci 5 manufacturing. The company has already transferred X system production to its East Coast hub near Atlanta. This year, Xi system production will move to Atlanta, too.

Over the next 18 months, the company will open new manufacturing facilities in California for the da Vinci 5 and Ion, he said. It will also complete line transfers for Ion and share price to Mexicali, Mexico.

Full story -

[wan] 23/1/2024 08:05

Two companies on Creo investor minds -

3 bellwether companies to watch as medtech earnings season begins
J&J, Intuitive Surgical and Abbott kick off this week with fourth-quarter reports.

Published Jan. 22, 2024

RBC Capital Markets analysts were similarly upbeat, writing about “positive momentum exiting 2023 for both procedure volumes and capital spending” in a note to investors last week.

A clearer picture of how the medtech industry fared in the fourth quarter and last year, and how companies expect to perform across 2024, will begin to emerge when J&J and Intuitive report results on Tuesday. Meanwhile, Abbott will report on Wednesday morning.

Here, we preview what to look out for in the first week of earnings for the industry:

Full story -

[master investor] 22/1/2024 21:24

Couldn't ask for any bigger than Intuitive (ISRG) 132 Billion mcap and Johnson and Johnson (JNJ) 391 Billion mcap. Either one of these two heavyweights could snap up CREO for multiples of current share price with lose change. A bidding war would be a mouthwatering prospect for share holders.

[hatfullofsky] 22/1/2024 20:45

NICE due before the end of Q1I liked the J&J comment "they are aware of us"

[19bihas] 20/1/2024 18:26

thanks for sharing. He touched on the NICE guidance being expected in the next 6 months and mentioned fast tracking, which is reassuring to hear given the NICE website has shown no updates since it was first announced.

Sounds like sales of the new speedboat slim are going well and they expect to meet guidance they had previously announced to the market...

I didn't know this personally, so sharing incase anyone else reading this didn't know either.. but after the question on J&J I did some googling and discovered CMR surgical have a collaboration agreement with one of the J&J companies (Ethicon)and of course CMR surgical also have a collab agreement with CREO....

all sounds positive to me.

[bloomberg2] 19/1/2024 20:26

https://youtu.be/fM0486BMyuM?si=opHn4MLFppZqCrI2

[mikeh30] 17/1/2024 19:25

MI - 25000 shares back In today the rest go in either higher or lower

[mikeh30] 16/1/2024 20:33

I really like the company. I just traded the chart. It got over heated so sold around 75000 shares between 47.5 and 49.5. I'll add them all back in around the 50ma. Good chance I miss news though. That's what the market is all about

[master investor] 16/1/2024 18:06

Good luck. Any buys at this level will make you money in 2024 that's for sure.

[mikeh30] 16/1/2024 17:04

I'm ready and waiting

[mikeh30] 16/1/2024 16:32

50ma 38.2 getting closer

[mikeh30] 12/1/2024 11:47

50ma now just under 38Between 40 and 42 is the next area to test before the next move up

[bloomberg2] 12/1/2024 08:06

No waiting for upload on utube

[wan] 12/1/2024 07:45

Intuitive is guiding for growth in procedures, robotic placements, and revenues -

Intuitive CEO: Strong robot placements offset bariatric surgery slowdown
Speaking at the J.P. Morgan Healthcare Conference, CEO Gary Guthart said the robotics company is also seeing strong growth in general surgeries.

Published Jan. 11, 2024

the robotic surgery leader is also seeing strong system placements and growth in general surgeries, CEO Gary Guthart told investors at the J.P. Morgan Healthcare Conference in San Francisco. The company preannounced that overall procedures assisted by its da Vinci robot grew 21% in the fourth quarter, above analysts’ expectations. The momentum prompted Intuitive to forecast an increase of about 13% to 16% in da Vinci procedures worldwide in 2024.

In 2023, Intuitive’s da Vinci procedure growth was 22%, as almost 2.29 million surgeries were performed with the systems.

The company placed 415 da Vinci robots with customers in the fourth quarter alone, up 12% from the same period a year ago. Preliminary fourth-quarter revenue rose 17% to about $1.93 billion.

William Blair analyst Brandon Vazquez said the preliminary fourth-quarter results beat expectations in nearly all categories. “The bottom line is that Intuitive is clearly heading into 2024 with strong momentum,” Vazquez said in a report to clients.
Full story -

Staying with Creo's growing collaboration with robotic surgery companies, notably with Intuitive, the world's largest robotic surgery company -


The following, also from the above Medtechdive link, provides food for thought -
At the J.P. Morgan event, Guthart declined to say whether Intuitive plans to roll out a next-generation multi-port robot in the year ahead, a topic of interest among investors.

“The fact that management didn’t comment leaves open the possibility for a launch this year,” J.P. Morgan analyst Robbie Marcus said in a research note after the presentation, pointing out that the executives made clear last year a new robot would not come in 2023.

[hatfullofsky] 12/1/2024 07:39

Did you join ? Anything of note ?

[bloomberg2] 11/1/2024 14:05

https://www.proactiveinvestors.co.uk/register/event_details/436

[bloomberg2] 11/1/2024 13:59

And a proactive presentation tonight!! Should be an interesting watch

[master investor] 11/1/2024 13:04

The markets were very poor over last 18 months for the reasons mentioned earlier. A lot of money left AIM as fear set in and people were scared to leave their cash in the market. Baillie Gifford selling down was probably the biggest reason the chart looks like it does. A persistent seller in a bear market moved the share price down. There are no swings on the chart from 100p to 18p. It's a different story now. Some very encouraging rns over the last few months. An over subscribed raise. Directors putting 2 million pounds of their own money in (you don't see this very often). Now fully funded into 2025 with FDA and European approval and of course NICE selecting speedboat for review. We have almost certainly seen institutional buying looking at the trades over the last few weeks. I will be amazed If we are not trading above 100p in the next 6 months and a sale of the company seems inevitable.

[dr biotech] 11/1/2024 08:20

Covid played a part, operations and regulatory progress wasn’t happening and the ongoing costs remained, hence cash ran low doubts rose as a going concern and the share price eroded over time.